Presentations & Publications

Publications

• Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024 Mar 7:S0140-6736(24)00063-1.
• Akhlaq A, Williams D, Clark WL, Khan H, Khanani AM, Walden L, Awh C, Graff JT, Graff JM, Wakabayashi T, Regillo C, Maass KF, Callaway NF, Gune S, Campochiaro PA. Exudation in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System or Monthly Injections. Am J Ophthalmol. 2024 Feb; 258: 158-172.
• Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. JAMA Ophthalmol. 2023 Sep 1;141(9):834-842.
• Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, Callaway NF, DeGraaf S, Ding HT, Fung AE, Gune S, Le Pogam S, Smith R, Willis JR, Barteselli G. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul;130(7):735-747.
• Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results from the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955
• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Long-Term Outcomes of Treat-And-Extend Ranibizumab With and Without Navigated Laser for Diabetic Macular Edema: TREX-DME 3-Year Results. Br J Ophthalmol. 2021 Feb;105(2):253-257.
• Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, LeHoang P, Ohno S, Rathinam SR, Ali Y, Mudumba S, Shams N, Nguyen QD; Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Study Group. Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. Ophthalmology. 2020 Oct;127(10):1405-1415.
• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 Jun;202:91-99.
• Payne JF, Clark WL, Bruce BB, Wykoff CC, Brown DM, Menke BM, Iverson SM, Allen KF, Boyer DS. Retinopathy regression with treat and extend ranibizumab for diabetic macular edema. Ophthalmology. 2018;125(8):1304-1306.
• Wykoff CC, Clark WL, Nielsen JS, Brill JV, Greene LS, Heggen CL. Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration. J Manag Car Spec Phar. 2018 Feb;24(2-a Suppl):S3-S15.
• Pielen A, Clark WL, Boyer DS, Ogura Y, Holz FG, Korobelnik JF, Stemper B, Asmus F, Rittenhouse KD, Ahlers C, Vitti R, Saroj N, Zeitz O, Haller JA. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol. 2017 Aug 23;11L1533-1540.
• Wykoff CC, OU WC, Croft DE, Payne JF, Brown DM, Clark WL, Abdelfattah NS, Sadda SR. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018 Apr; 102(4):460-464.
• Clark WL, Boyer DS, Kaiser PK. Controversies in using off-label intravitreous bevacizumab for patients with diabetic macular edema. JAMA Ophthalmol. 2017 Mar 1; 135(3):291.
• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 year outcomes. Ophthalmology. 2017 Jan;124(1):74-81.
• Nguyen QD, Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, LeHoang P, Ohno S, Rathinam SR, Thurau S, Abraham A, Wilson L, Yang Y, Shams N; Sirolimus study assessing double-masked uveitis treatment (SAKURA) Study Group. Intravitreal Sirolimus for noninfectious uveitis: a phase III Sirolimus study assessing double-masked uveitis treatment (SAKURA). Ophthalmology. 2016 Nov;123(11):2413-2423.
• Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, Wang R, Clark WL, Boyer DS; ENDURANCE Study Group. Outcomes with as-needed aflibercept and macular laser following the phase 111 VISTA DME Trial: ENDURANCE 12-Month Extension Study. Am J Ophthalmol. 2017 Jan;173:56-63.
• Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Cheng Y, Campochiaro PA. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016;123:330-6.
• Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR, T-REX AMD Study Group. Prospective trial of treat and extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 2015;122:2514-22.
• Patterson M, Bergstrom CS, Clark WL, Grossniklaus HE, Payne JF. Severe panuveitis, retinal vasculitis, and optic disk granuloma secondary to sarcoidosis. Retin Cases Brief Rep 2015;epub ahead of print.
• Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti WR, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Zhu X, Haller JA. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 2015;122:538-44.
• Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, for the BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment. A randomized clinical trial. JAMA Ophthalmol 132:1327-33.
• Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121:1414-1420.
• Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phased 3 COPERNICUS study. Am J Ophthalmol 2012;119:1024-32.
• Boyer D, Heier J, Brown D, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sanbrink R, Zhu X, Beckman K, Haller JA. VEGF Trap-Eye for macular edema secondary to central retinal vein occlusion: 6-month results of the phase 3 COPERNICUS study. Ophthalmology 2012;119:1024-32.
• Zaldivar, RA, Michaels ME, Grant K, Clark WL, Grossniklaus HE. Metastatic breast carcinoma to the vitreous. Retina 2004;24:226-30.
• Sullivan P, Clark WL, Kaiser PK. Bilateral endogenous endophthalmitis caused by HACEK microorganism. Am J Ophthalmol 2002;133:144-5.
• Clark WL, Kaiser PK, Flynn HW Jr., Belfort A, Miller D, Meisler DM. Treatment strategies and visual outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Ophthalmology 1999;106:1665-1670.
  -Clark, WL, Scott IU, Murray TG, Rosa Jr. RH, Siatkowski RM, Langham MR. Primary intraocular post-transplant lymphoproliferative disorder. Arch Ophthalmol 1998;116: 1667-1669.
• Krol BJ, Murad S, Walker LC, Marshall MK, Clark WL, Pinnell SR, Yeowell HN. The expression of a functional, secreted lysyl hydroxylase in a baculovirus system. J Invest Dermatol 1996;106:11-16.
• Clark WL, Peiffer RL. Cellular and tissue response to intraocular lenses. Progress in Veterinary and Comparative Ophthalmology 1995;5:50-59.
• Yeowell HN, Ha V, Clark WL, Marshall MK, Pinnell SR. Sequence analysis of a cDNA for lysyl hydroxylase isolated from human skin fibroblasts from a normal donor: differences from human placental lysyl hydroxylase cDNA. J Invest Dermatol 1994; 102:382-384.

Presentations

• Clark WL. First Ever Home OCT- Guided Managment of Treatment Experienced Neovascular AMD Patients. American Academy of Ophthalmology Annual Meeting, San Francisco, CA. November 4, 2023.
• Clark WL. Retina Update 2023. Kiawah Eye 2023. Kiawah Island, South Carolina, June 1, 2023.
• Clark WL. AI – Home OCT. Atlantic Coast Retina Club, Macula 2023. Boston, MA, February 4, 2023.
• Clark WL. Association Between Diabetic Retinopathy Severity Scale Changes and Visual/Anatomic Outcomes in Patients with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy: A Post Hoc Analysis of PANORAMA. The Retina Society 55th Annual Meeting. Pasadena, CA, November 3rd. 2022.
• Clark WL. Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study. American Society of Retinal Specialists 40th Annual Meeting. New York City, NY, July 16th, 2022.
• Clark WL. Retina Update 2022. Kiawah Eye 2022. Kiawah Island, South Carolina, June 1, 2022.
• Clark WL. Impact of Nonperfusion and Leakage Areas on Diabetic Macular Edema/Vision-Threatening Complications in Nonproliferative Diabetic Retinopathy (NPDR). American Society of Retinal Specialists 39th Annual Meeting. San Antonio, Texas, October 9th, 2021.
• Clark WL. The Archway Phase 3 Trial of the Port Delivery System with Ranibizumab (PDS) for Neovascular Age-Related Macular Degeneration (nAMD): Updated Safety and Efficacy Results. The Retina Society 54th Annual Meeting. Chicago, IL, October 1st, 2021.
• Clark WL. Retina Update 2021. Kiawah Eye 2021. Kiawah Island, South Carolina, June 1, 2021.
• Clark WL, Gallagher J, Marcus D, Modjtahedi B, Pieramici D, Sharma S. Diabetic Retinopathy 1 Symposium. American Society of Retinal Specialists 38th Annual Meeting. Virtual, July 25th, 2020.
• Clark WL. Intravitreal Aflibercept Injection for Nonproliferative Diabetic Retinopathy: 52-week Results from the Phase 3 PANORAMA Study. The Retina Society 52nd Annual Scientific Meeting. London, England, September 13, 2019.
• Clark WL, Wang P, Haskova Z, Ruiz C. Individualized Ranibizumab Treatment in Patients With RVO Leads to Visual Acuity Outcomes Consistent With a Monthly Dosing Regimen. . American Society of Retinal Specialists 34th Annual Meeting. San Francisco, California, August 11, 2016.
• Clark WL, Abraham P, Brown D, Faber D, Marcus D. Evaluation of long-term treatment with intravitreal aflibercept injection (IAI) in patients completing the VIEW 1 and VIEW extension studies: one-year results of the RANGE study. The Retina Society 48th Annual Scientific Meeting. Paris, France, October 9, 2015.
• Clark WL, Brown D, Stemper B. Intravitreal aflibercept for macular oedema due to branch retinal vein occlusion. European Association for Vision and Research Annual Meeting. Nice, France, October 4, 2014
• Clark WL. Early visual acuity improvements in RVO patients treated with ranibizumab in SHORE trial. The Retina Society 47th Annual Scientific Meeting. Philadelphia, Pennsylvania, September 14, 2014
• Clark WL. Un nueva perspectiva en el manejo de la patologia macular. Sociedad Argentina de Oftalmologia Curso Annual. Buenos Aires, Argentina, August 1, 2014.
• Clark WL. Surgical displacement of submacular hemorrhage with tissue-plasminogen activator. In Macula, presente y futuro. Sociedad Argentina de Oftalmologia Curso Annual. Buenos Aires, Argentina, August 1, 2014
• Clark WL. Long-term safety of intravitreal aflibercept injection in neovascular AMD. American Academy of Ophthalmology Annual Meeting. New Orleans, Louisiana, November 16, 2013.
• Clark WL. Intravitreal aflibercept for macular edema due to branch retinal vein occlusion: 24-results of the VIBRANT study. Retina 2013: Let the Good Times Roll. American Academy of Ophthalmology Annual Meeting Subspecialty Day. New Orleans, Louisiana, November 13, 2013.
• Clark WL. Factors affecting the frequency of intravitreal aflibercept injections (IAI) during the PRN phase of the COPERNICUS and GALILEO central retinal vein occlusion (CRVO) studies. The Retina Society 46th Annual Scientific Meeting. Beverly Hills, California, September 27, 2013
• Clark WL, Ehrlich JS. Intravitreal ranibizumab modifies the natural history of diabetic retinopathy: 36-month data from the RISE and RIDE phase III trials. American Society of Retinal Specialists 31st Annual Meeting. Toronto, Canada, August 27, 2013
• Clark WL. Retina Update 2013. Kiawah Eye 2013. Kiawah Island, South Carolina, May 31, 2013.
• Clark WL. Two-year results of the COPERNICUS study evaluating intravitreal aflibercept injection (IAI) for macular edema secondary to central retinal vein occlusion (CRVO). Association for Research and Vision in Ophthalmology 2013 Annual Meeting. Seattle, Washington, May 8, 2013.
• Boyer D, Holz F, Brown D, Heier J, Haller J, Clark WL, Ogura Y, Korobelnik J-F, Simader C, Roider J. Intravitreal Aflibercept injection (IAI) for macular edema secondary to central retinal vein occlusion (CRVO): results of COPERNICUS 2-year and GALILEO 10-month. 36th Annual Macula Society Meeting 2013. Dana Point, California.
• Clark WL, Heier J, Boyer D, Stemper B, Vitti R, for the COPERNICUS Study Group. Intravitreal VEGF trap-eye in central retinal vein occlusion: results of the phase 3 COPERNICUS study. The 8th International Symposium of Ophthalmology, Hong Kong, December 16, 2012.
• Boyer DS, Haller JA, Brown DM, Heier JS, Clark WL, Vitti R, Berliner AJ, Zeitz O, Groetzbach. 1-year results of the phase 3 COPERNICUS study: intravitreal aflibercept injection in CRVO. Macula Society 2012, Jersalem, Israel.
• Clark WL. Retina Update 2012. Kiawah Eye 2012. Kiawah Island, South Carolina, June 1, 2012.
• Brown DM, Haller JA, Boyer DS, Heier JS, Clark WL, Vitti R, Berliner AJ, Zeitz O, Groetzbach G. Intravitreal aflibercept injection in central retinal vein occlusion: 1-year results of the phase 3 COPERNICUS study. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, Florida, May 5, 2012.
• Haller JA, Boyer DS, Brown DM, Heier JS, Clark WL, Vitti R, Berliner AJ. VEGF Trap-Eye in Central Retinal Vein Occlusion: One-Year Results of the Phase 3 COPERNICUS Study. Amierican Academy of Ophthalmology, Orlando, Florida, October 24, 2011.
• Clark WL. VEGF Trap Eye for Retinal Vein Occlusion: Copernicus and Galileo. American Academy of Ophthalmology Subspecialty Day, Retina 2011: The Magical World of Retina. Orlando, Florida, October 21, 2011.
• Clark WL, Do D, Heier J, Vitti R, Berliner A. VEGF Trap-Eye in Diabetic Macular Edema: One-year Results of the DAVINCI Study. 44th Annual Scientific Session of The Retina Society. Rome, Italy, September 22, 2011.
• Boyer DS, Haller J, Brown D, Heier J, Clark WL, Vitti R, Berliner A. VEGF Trap-eye in Central Retinal Vein Occlusion: Results from the Phase 3 COPERNICUS Study. 44th Annual Scientific Session of the The Retina Society. Rome, Italy, September 22, 2011.
• Clark WL. VEGF Trap-Eye in CRVO: 1-year results of the Phase III COPERNICUS Trial. 29th Annual Meeting, American Society of Retinal Specialists. Boston, Massacheusetts, August 22, 2011.
• Clark WL. The Future of Diabetic Macular Edema Therapy: Do We Still Need a Laser? Kiawah Eye 2011. Kiawah Island, South Carolina, June 4, 2011.
• Clark WL. Future Directions in AMD Management. Kiawah Eye 2011. Kiawah, South Carolina, June 4, 2011.
• Haller JA, Boyer DS, Heier JS, Brown DM, Clark WL, Vitti R. VEGF Trap-Eye in CRVO: Primary Endpoint Results of the Phase III COPERNICUS Stydy. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, Florida, May 03, 2011.
• Clark WL. Intravitreal Steroids: Indications and Results. Kiawah Eye 2010. Kiawah Island, South Carolina, May 14, 2010.
• Clark WL. Risk Factor Analysis for Visual Acuity and OCT Outcomes Following Vitrectomy for Diabetic Macular Edema in the DRCR Network. American Academy of Ophthalmology, San Francisco, California, October 25,2009.
• Clark WL. Future Directions in Retinopathy of Prematurity Management. Kiawah Eye 2009. Kiawah Island, South Carolina, May 28, 2009.
• Clark WL. Emerging Therapies for Age-Related Macular Degeneration. Storm Eye/American Society of Cataract and Refractive Surgery Clinical Update. Kiawah Island, South Carolina, May 29, 2008.
• Wroblewski JJ, Wells III JA, Gonzales CR, Clark WL, Schwartz SD. Pegaptanib for the treatment of macular edema secondary to branch retinal vein occlusion: interim results of an open label study. 25th Annual Meeting, American Society of Retinal Specialists, Indian Wells, California, December 3, 2007.
• Clark WL. Anti-VEGF Therapy for Retinal Diseases. Storm Eye/American Society of Cataract and Refractive Surgery Clinical Update. Kiawah Island, South Carolina, May 29, 2007.
• Clark WL. Anti-VEGF Therapy for Age-Related Macular Degeneration. Greenwood Medical Society. Greenwood, South Carolina, October 17, 2006.
• Clark WL, Yoser S, Bowie E. Retina Update. American Society of Cataract and Refractive Surgery/Storm Eye Institute Clinical Update 2006. Kiawah Island, South Carolina, June 1, 2006.
• Clark WL. Anti-VEGF Therapy: A New Era in AMD Management and Symposium on AMD and VEGF. Reuniao Cientifica, Servicio de Oftalmologia do Hospital de S. Joao/F.M.P. Porto, Portugal, September 16, 2005
• Clark WL. Photodynamic Therapy: Mono and Combination Therapies. Retina Techs of the Carolinas Meeting, Columbia, South Carolina, August 20, 2005
• Wells JA, Clark WL, Wroblewski JJ. Inferior displacement of submacular hemorrhage. XXIII Meeting of the Club Jules Gonin, Lausanne, Switzerland, September 2002.
• Clark WL, Lewis H. Macular hole after limited macular translocation in patients with previous photocoagulation. Annual Residents and Alumni Day, Cole Eye Institute, The Cleveland Clinic Foundation, Cleveland, Ohio, June 9, 2000.
• Clark WL. Introduction to photodynamic therapy. Photodynamic Therapy of Age-Related Macular Degeneration: A Complete Training Course. Cole Eye Institute, The Cleveland Clinic Foundation, Cleveland, OH, June 3, 2000.
• Clark WL, Flynn HW Jr., Kaiser PK, Belfort A, Miller D. Intravitreal dexamethasone in the treatment of acute-onset postoperative endophthalmitis. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, Florida, May, 2000. 35th Annual Residents’ Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 18, 1999.
• Ysasaga JE, Clark WL, Aaberg TM Jr., Rubsamen P, Cousins S. Pediatric ocular trauma. 35th Annual Residents’ Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 18, 1999.
• Curtin VT, Clark WL, Rosa RH Jr. Post organ transplantation lymphoproliferative lesion of iris. Eastern Ophthalmic Pathology Society. Sanibel-Captiva Islands, FL, October 22-25, 1998.
• Clark WL, Flynn HW Jr., Belfort A, Miller D, Kaiser PK. Treatment strategies and visual outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Annual Meeting, American Academy of Ophthalmology, New Orleans, LA, November 8, 1998. 34th Annual Residents’ Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 12, 1998. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 19, 1998.
• Ysasaga JE, Clark WL, Aaberg TM Jr., Rubsamen P, Cousins S. Risk factors for poor visual outcome in pediatric penetrating trauma. 34th Annual Residents’ Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 12, 1998.
• Kaiser PK, Clark WL, Meisler D, Flynn HW Jr. Management controversies in Propionibacterium acnes endophthalmitis. Cleveland Clinic Division of Ophthalmology Annual Residents and Alumni Meeting, Cleveland, OH, June 12, 1998.
• Aaberg TM Jr., Clark WL, Rubsamen P. Penetrating and perforating injuries in pediatric patients. Aspen Retinal Detachment Society, Aspen, CO, March 2-3, 1998.
• Clark WL, Kaiser PK, Miller D, Flynn HW Jr. Causative organisms and antibiotic sensitivities of culture positive endophthalmitis. 33rd Annual Residents’ Days, Bascom Palmer Eye Institute, Coral Gables, FL, June 1997. Association for Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 16, 1997.
• Clark WL, Pinnell SR, Yeowell HN. Sequence analysis of a full length cDNA for lysyl hydroxylase isolated from human skin fibroblasts. American Geriatric Society/American Federation for Aging Research National Meeting, Washington, DC, November 17, 1993.

Publications

• Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW, (Fishburne BC was a collaborator). Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. ; Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2016 Feb;134(2):127-34.
• Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA, (Fishburne BC was a collaborator). Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol. 2015 Aug;133(8):888-96.
• Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL,Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. (Fishburne BC was a collaborator). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Diabetic Retinopathy Clinical Research Network, N Engl J Med. 2015 Mar 26;372(13):1193-203.
• Danis RP, Domalpally A, Chew EY, Clemons TE, Armstrong J, SanGiovanni JP, Ferris FL 3rd, (Fishburne BC was a principle investigator) Methods and reproducibility of grading optimized digital color fundus photographs in the AgeRelated Eye Disease Study 2 (AREDS2 Report Number 2). AREDS2 Study Group Invest Ophthalmol Vis Sci. 2013 Jul 8;54(7):4548-54.
• Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD. (Fishburne BC was a collaborator). Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. Diabetic Retinopathy Clinical Research Network. Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6168-73.
• Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME. (Fishburne BC was a collaborator). Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010 Jun;117(6):1087-1093.
• Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Kollman C, Wells JA 3rd. (Fishburne BC was a collaborator) Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol. 2009 Feb;127(2):132-40.
• Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H (Fishburne BC was a collaborator). Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Diabetic Retinopathy Clinical Research Network. Ophthalmology. 2008 Aug;115(8):1366-71,
• Diabetic Retinopathy Clinical Research Network. (Fishburne BC was a collaborator) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008 Sep;115(9):1447-9,
• Fishburne BC, Mitrani AA, Davis JL. Cytomegalovirus retinitis after cardiac transplantation. Am J Ophthalmol. 1998 Jan;125(1):104-6.
• Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997 Sep;115(9):1152-6.
• Fishburne BC, Winthrop KL, Robertson JE. Atrophic fundus lesions associated with untreated retinopathy of prematurity. Am J Ophthalmol. 1997 Aug;124(2):247-9.
• Morgan MA, Silavin SL, Dormer KJ, Fishburne BC, Fishburne JI Jr. Effects of labetalol on uterine blood flow and cardiovascular hemodynamics in the hypertensive gravid baboon. Am J Obstet Gynecol. 1993 May;168(5):1574-9.

Publications

• Thanos A, Todorich B, Hypes SM, Yonekawa Y, Trese M. Retinal Vascular Tortuosity and Exudative Retinopathy in a Family with Dyskeratosis Congenita Masquerading as Familial Exudative Vitreoretinopathy. Retin Cases Brief Rep. 2017 Winter;11 Suppl 1:S187-190; PubMed ID 27685501.
• Hypes SM, Nasser O, Hanna N, Lawhon W, Bouhenni R, Hertle R. Post Mortem Vitreous Bevacizumab Levels of an Infant Treated for Retinopathy of Prematurity. J AAPOS. 2016 Dec; 20(6):537-539; PubMed ID 27810420.
• Yonekawa Y, Hypes SM, Abbey AM, Williams GA, Wolfe JD. Exacerbation of Macular Edema Associated with Hyperbaric Oxygen Therapy. Clin Exp Ophthalmol. 2016 Sept;44(7):625-626; PubMed ID 26844686.
• Koval MS, El Sayyad FF, Bell NP, Chuang AZ, Lee DA, Hypes SM, Grover DS, Baker LA, Huddleston SM, Budenz DL, Feldman, RM. Risk Factors for Tube Shunt Exposure: A Matched Case-Control Study. J Ophthalmol. 2013; Article ID:196215; PubMed ID 23970955.

Presentations & Posters

• 1/31/18 –Presentation – Review of Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy. LSU Ophthalmology Resident Grand Rounds. New Orleans, LA
• 10/18/17– Presentation – Review of Toxoplasma Chorioretinitis. LSU Ophthalmology Resident Grand Rounds. New Orleans, LA
• 5/6/16– Poster – Post Mortem Vitreous Bevacizumab Levels of an Infant Treated for Retinopathy of Prematurity. Annual Clinical Assembly. AOCOO-HNS. Phoenix, AZ
• 5/2/16– Poster– Exacerbation of Macular Edema Associated with Hyperbaric Oxygen Therapy. ARVO. Seattle, WA.
• 7/13 – 6/14–Presentations – Bi-monthly ophthalmology lectures for Michigan State University medical students. Oakwood Southshore Medical Center. Trenton, MI.
• 1/11/13 – Presentation – "Diagnosis and Management of the Red Eye" Education Day. Charleston General Hospital. Charleston, WV.

Publications

• Central Serous Papillopathy, a Variant of Central Serous Chorioretinopathy. D Johnson, V Patel. Journal of Neuro-Ophthalmology: June 2009 - Volume 29 - Issue 2 - 155-156.
• Rhegmatogenous Retinal Detachment after Laser Prophylaxis for Retinoschisis. D Johnson, J Nieto, M Ip. Archives of Ophthalmology. 2008;126(12):1775-1776.
• Uveal Melanoma Masquerading as Pigment Dispersion Glaucoma. DL Johnson, M Altaweel, A Neekrha, D Albert. Archives of Ophthalmology. June 2008.

Presentations

• Diabetes and Your Eyes. Presented at Annual Florence County Council on the Aging. March 2011.
• Eye Disease in the Elderly Population. Presented at Orangeburg County Council on Aging. Orangeburg, SC. October 2008-2011.
• Understanding Diabetic Retinopathy. Presented at the Annual African American Diabetes Conference, Department of Health and Environmental Control, Columbia, SC. November 2008-2009.
• Update on Diagnosis and Treatment of Diabetic Retinopathy. Presented at the Annual Ophthalmology Update for Primary Care Practitioners, University of South Carolina School of Medicine, Columbia, SC. November 2008.
• Acute Posterior Multifocal Placoid Pigment Epitheliopathy. Department of Ophthalmology, University of Wisconsin, Madison, WI. March 2008
• White Dot Syndromes. Presented at Ophthalmic Technicians Continuing Nursing Education, University of Wisconsin, Madison, Wisconsin. January 2008.
• Ocular Manifestations of Syphilis. Presented at American Society of Retina Specialists, Mentoring in Ophthalmology Fellowship Program, Palm Springs, California. December 2007.
• Update on Vitreoretinal Surgical Techniques. University of Wisconsin Department of Ophthalmology, Madison, Wisconsin. August 2007.
• OPHTEC Model 311 Artificial Iris Lens For the Treatment of Visual Disturbances Resulting From Partial or Total Absence of the Human Iris. Presented at Grand Rounds, University of Wisconsin, Madison,Wisconsin. February 2007.
• Update on Diabetic Retinopathy. Department of Endocrinology, University of Wisconsin, Madison, Wisconsin. November 2006, September 2007.
• Ocular Structural Changes during Microkeratome Suction Ring Placement in LASIK. Jason A. Evangelista, MD, Richard M. Davis, MD, David L. Johnson, MD. American Society of Cataract and Refractive Surgeons, San Francisco, California. April 2006.
• Hyperbaric Oxygen Therapy and the Eye. David Johnson, MD. Department of Hyperbaric Medicine. Palmetto Richland Memorial Hospital, Columbia, South Carolina. Lecture Series, 2005-2006.
• Demographics and Outcomes of Eye Trauma Victims in South Carolina. University of South Carolina School of Medicine, Department of Ophthalmology, Columbia, South Carolina. 2004.
• Ocular Pharmacology and Toxicology of Fireworks Injuries. V.A. Pakalnis, R.C. Tripathi, D. Johnson. Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, South Carolina. Presented at International Society of Ocular Toxicology, 2004.
• Drug Induced Glaucomas. Ramesh Tripathi, MD, Brenda Tripathi, PhD, Chris Haggerty, MD, David Johnson, MD. Biannual Ophthalmology Update, Columbia, South Carolina. January 2003.
• Examining Patient’s Satisfaction With as Well as the Effectiveness of Using a Mobile Screening Unit with a Non-Mydriatic Fundoscopic Photography to Screen for Diabetic Retinopathy in a Rural Population. University of South Carolina School of Medicine, Department of Family Medicine, Department of Ophthalmology, Columbia, South Carolina. July 2001.
• Examining Factors That Contribute to the High Rate of Missed Appointments in a Community Based Primary Care Practice and the Effect it has on Those Patients With Chronic Conditions That Require Close Follow Up. University of South Carolina School of Medicine, Department of Family Practice, Columbia, South Carolina. April 2001.

Peer-Reviewed

• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group. Randomized Trial of Treat & Extend Ranibizumab With & Without Navigated Laser Versus Monthly Dosing for DME: TREX-DME 2 Year Outcomes. Am J Ophthalmol 2019:202;91-99.
• Abdelfatta NS, Hariri AH, Al-Sheikh M, Pitetta S, Ebraheem A, Wykoff CC, Sadda SR, TREX-AMD Study Group. Topographic Correspondence of Macular Atrophy with Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD trial. Am J Ophthalmol 2018;192:84-90.
• Payne JF, Clark WL, Bruce BB, Wykoff CC, Brown DM, Menke BM, Iverson SM, Allen KF, Boyer DS, TREX-DME Study Group. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2018;125(8):1304-1306.
• Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC, Diabetic Retinopathy Clinical Research Network. Ophthalmology 2018;125(7):1054-1063.
• Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM, Clark WL, Abdelfattah NS, Sadda SR, TREX-AMD Study Group. Neovascular Age-Related Macular Degeneration Management in the Third Year: final results from the TREX-AMD randomised trial. Br J Ophthalmol 2018;102(4):460-464.
• Menke B, Walters A, Payne JF. Paradoxical Anatomic Response to Topical Carbonic Anhydrase Inhibitor in X-linked Retinoschisis. Ophthalmic Surg Laser Imaging 2018;49(2):142-144.
• Ou WC, Brown DM, Payne JF, Wykoff CC. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol 2017;180:8-17.
• Kozak I, Payne JF, Schatz P, Al-Kahtani E, Winkler M. Teleophthalmology image-based navigated retinal laser therapy for diabetic macular edema: A concept of retinal telephotocoagulation. Graefes Arch Clin Exp Ophthalmol 2017;255(8):1509-1513.
• Abdelfattah NS, Al-Sheikh M, Pietta S, Mousa A, Sadda SR, Wykoff CC, Treat-and-Extend Age Related Macular Degeneration Study Group. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology 2017;124(2):215-223.
• Wykoff CC, Ou WC, Brown DM, Croft DE, Wang R, Payne JF, Clark WL, Abdelfattah NS, Sadda SR. Randomized Trial of Treat and Extend versus Monthly Dosing for Neovascular Age Related Macular Degeneration: TREX-AMD 2-Year Results. Ophthalmology Retina 2017; 1(4):314-321.
• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 year Outcomes. Ophthalmology 2017;124(1):74-81.
• Wells JA, Glassman AR, Jampol LM, et al., Diabetic Retinopathy Clinical Research Network. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol 2016;134(2):127-134.
• Zhang L, Li Y, Payne JF, Srivastava SK, Fan X, Fung J, Li X, Kern TS, Lin F. Presence of Retinal Pericyte-Reactive Autoantibodies in Diabetic Retinopathy Patients. Sci Rep 2016;6:20341.
• Patterson M, Bergstrom CS, Clark WL, Grossniklaus HE, Payne JF. Severe Panuveitis, Retinal Vasculitis, and Optic Disc Granuloma Secondary to Sarcoidosis. Retin Cases Brief Rep 2016;10(4):341-344.
• Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR, TREX-AMD Study Group. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-year results. Ophthalmol 2015;122(12):2514-2522.
• Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015;372(13):1193-1203.
• Sawhney GK, Payne JF, Ray R, Mehta S, Bergstrom CS, Yeh S. Combination Anti-Vascular Endothelial Growth Factor and Corticosteroid Therapy for Idiopathic Retinal Vasculitis, Aneurysms and Neuroretinitis (IRVAN) Syndrome. Ophthalmic Surg Lasers Imaging Retina 2013;44(6):599-602.
• Furtado JM, Davies MH, Choi D, Lauer AK, Appukuttan B, Bailey ST, Rahman HT, Payne JF, Stempel AJ, Mohs K, Powers MR, Yeh S, Smith JR. Imaging Retinal Vascular Changes in the Mouse Model of Oxygen-Induced Retinopathy. Trans Vis Sci Tech 2012;1:2,5.
• Payne JF, Rahman HT, Grossniklaus HE, Bergstrom CS. Retinal Metastasis Simulating Cytomegalovirus Retinitis. Ophthalmic Surg Lasers Imaging. 2012;43:e90-93.
• Payne JF, Ray R, Watson DG, Rimler E, Delille C, Cleveland J, Lynn MJ, Tangpricha V, Srivastava SK. Vitamin D Insufficiency in Diabetic Retinopathy. Endocr Pract 2012;18(2):185-93.
• Payne JF, Bruce BB, Yeh S. Author Response: Retinal Thickness Measurement using OCT. Invest Ophthalmol Vis Sci 2012;53(2):854-5.
• Kim J, Payne JF, Yan J, Barnes CS. Negative Electroretinograms in the Pediatric and Adult Population. Doc Ophthalmol 2012;124(1):41-8.
• Jung CS, Payne JF, Bergstrom CS, Cribbs BE, Yan J, Hubbard GB, Olsen TW, Yeh S. Multimodality Diagnostic Imaging in Unilateral Acute Idiopathic Maculopathy. Arch Ophthalmol 2012;130(1):50-6.
• Payne JF, Bruce BB, Lee LBK, Yeh S. Logarithmic Transformation of Spectral-Domain Optical Coherence Tomography Data in Uveitis-Associated Macular Edema. Invest Ophthalmol Vis Sci 2011;52(12):8939-43.
• Payne JF, Tangpricha V, Cleveland J, Lynn MJ, Ray R, Srivastava SK. Serum Insulin-Like Growth Factor-I in Diabetic Retinopathy. Mol Vis 2011;17:2318-24.
• Payne JF, Srivastava SK, Wells JR, Grossniklaus HE. Rosai-Dorfman Disease Simulating Nodular Scleritis and Panuveitis. Arch Ophthalmol 2011;129(4):518-20.
• Payne JF, Hubbard GB, Aaberg TM Sr, Yan J. Clinical Characteristics of Hydroxychloroquine Retinopathy. Br J Ophthalmol 2011;95(2):245-50.
• Payne JF, Bergstrom C, Yan J, Aaberg TM Sr, Srivastava SK. Residual Triamcinolone Acetonide Sequestered in the Fovea After Macular Hole Repair. Retina 2011;31(1):148-53.
• Payne JF, Keenum DG, Sternberg P Jr., Thliveris A, Kala A, Olsen TW. Concentrated Intravitreal Amphotericin B for Fungal Endophthalmitis. Arch Ophthalmol 2010;128(12):1546-50.
• Payne JF, Hutchinson AK, Hubbard GB, Lambert SR. Outcomes of Cataract Surgery Following Radiation Treatment for Retinoblastoma. J AAPOS 2009;13(5):454-458e.
• Kelty PJ, Payne JF, Trivedi RH, Kelty J, Bowie EM., Burger BM. Macular Thickness Assessment in Healthy Eyes Based on Ethnicity using the STRATUS OCT Optical Coherence Tomography. Invest Ophthalmol Vis Sci 2008;49(6):2668-72.
• Ledoux DM, Trivedi RH, Wilson ME, Payne JF. Pediatric Cataract Extraction with Intraocular Lens Implantation: Visual Acuity Outcomes When Measured at Four Years and Older. J AAPOS 2007;11(3):218-24.
• Payne JF, Shields CL, Eagle RC, Shields JA. Orbital Lymphoma Simulating Thyroid Orbitopathy. Ophthal Plast Reconstr Surg 2006;22(4):302-04.
• Squires CE, Escobar GP, Payne JF, Leonardi RA, Goshorn DK, Mingoia JT, Flack EC, Lindsey ML. Altered Fibroblast Function Following Myocardial Infarction. J Mol Cell Cardiol 2005;39(4):699-707.

Non-Peer Reviewed Publications

• Wells J, Pearce W, Payne JF, Yeh S. Morning Rounds: The case of the pregnant woman with a visual disturbance. EyeNet. January 2016.
• Payne JF, Clark WL. Computer-Navigated Laser for DME: How we got here. Retina Specialist. November 2015.
• Payne JF, Clark WL. Intravitreal Aflibercept for Diabetic Macular Edema. Retinal Physician. January 2015.
• Payne JF, Tangpricha V. Vitamin D and Diabetic Retinopathy. In: Preedy VR, ed. The Handbook of Nutrition, Diet, the Eye and Vision. London, England: Elsevier, Inc. New York, NY: Elsevier. 2014.
• Payne JF, Hubbard GB, Olsen TW. General Considerations in Ophthalmic Surgery. In: Dodson T, Lubin M, Winawer N, eds. Medical Management of the Surgical Patient: A Textbook of Perioperative Medicine. 5th ed. Cambridge, MA: Cambridge University Press. 2013.
• Payne JF, Srivastava SK. Cancer Associated Retinopathy. In: Garg S, Bogdaghi B, Rathinam S, Sen N, Nussenblatt R, eds. Uveitis: Color Atlas and Synopsis of Clinical Ophthalmology. Philadelphia, PA: Lippincott Williams and Wilkens. 2011.

Presentations

• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group. Randomized Trial of Treat & Extend Ranibizumab With & Without Navigated Laser Versus Monthly Dosing for DME: TREX-DME 3 Year Outcomes. Presented at the annual meeting of the American Academy of Ophthalmology. Chicago, IL; October 2019.
• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 year Outcomes. Presented at the annual meeting of the American Academy of Ophthalmology. Chicago, IL; October 2016.
• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 year Outcomes. Presented at the annual meeting of The Retina Society. San Diego, CA; September 2016.
• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 year Outcomes. Presented at the annual meeting of the American Society of Retina Specialists. San Francisco, CA; August 2016.
• Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, TREX-DME Study Group. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 year Outcomes. Presented at the annual meeting of the Association for Research in Vision and Ophthalmology. Seattle, WA; May 2016.
• Payne JF. Severe Panuveitis, Retinal Vasculitis, and Optic Disc Granuloma Secondary to Sarcoidosis. Presented at the annual meeting of The Retina Society. Los Angeles, CA. September, 2013.
• Davies MH, Furtado JM, Yeh S, Stempel AJ, Mohs K, Payne JF, Rahman HT, Powers MR, Smith JR. Topical Endoscopic Fundus Imaging in Murine Oxygen-Induced Retinopathy. Presented at the annual meeting of the Association for Research in Vision and Ophthalmology. Ft. Lauderdale, FL; April 2012.
• Payne JF, Bruce BB, Lee LBK, Yeh S. Logarithmic Transformation of Spectral-Domain Optical Coherence Tomography Data in Uveitis-Associated Macular Edema. Presented at the annual meeting of the American Society of Retina Specialists. Boston, MA; August 2011.
• Payne JF, Jung CS, Bergstrom CS, Cribbs BE, Yan J, Hubbard GB, Olsen TW, Yeh S. Multimodality Diagnostic Imaging in Unilateral Acute Idiopathic Maculopathy. Presented at the annual meeting of the American Society of Retina Specialists. Boston, MA; August 2011.
• Payne JF, Tangpricha V, Cleveland J, Lynn MJ, Ray R, Srivastava SK. Serum Insulin-Like Growth Factor-I in Diabetic Retinopathy. Presented at the annual meeting of the Association for Research in Vision and Ophthalmology. Ft, Lauderdale, FL; April 2011.
• Payne JF, Ray R, Watson DG, Rimler E, Delille C, Cleveland J, Lynn M, Tangpricha V, Srivastava SK. Vitamin D Insufficiency in Diabetic Retinopathy. Presented at the annual meeting of the American Academy of Ophthalmology. Chicago, IL; October 2010.
• Payne JF, Barnes C, Yan J. The Clinical Significance of Negative Electroretinograms. Presented at the annual meeting of the American Academy of Ophthalmology. San Francisco, CA; October 2009.
• Payne JF, Bergstrom C, Yan J, Aaberg TM Sr, Srivastava SK. Residual Triamcinolone Acetonide Sequestered in the Fovea After Macular Hole Repair: Outcomes of Surgery. Presented at the annual meeting of the Association for Research in Vision and Ophthalmology. Ft. Lauderdale, FL; May 2009.
• Payne JF, Lo WR, Yan J. Hydroxychloroquine and Chloroquine Retinal Toxicity: Visual stabilization and recovery following drug cessation. Presented at the annual meeting of Association for Research in Vision and Ophthalmology. Ft. Lauderdale, FL; April 2008.
• Payne JF, Saunders RA. Modification of a Bishop Tendon Tucker for Quantitative Measurements of Superior Oblique Tendon Laxity. Presented at the pediatric ophthalmology meeting of the American Academy of Ophthalmology. New Orleans, LA; November 2007.
• Ledoux DM, Trivedi RH, Wilson ME, Payne JF. Pediatric Cataract Extraction with Intraocular Lens Implantation: Visual Acuity Outcomes When Measured at Four Years and Older. Presented at the annual meeting of the American Society of Cataract and Refractive Surgeons. San Francisco, CA; March 2006.
• Payne JF, Kelty PJ, Saunders RA. The Use of Adjustable Sutures in Adult Strabismus: Is it the standard of care?. Presented at the annual Storm Eye Institute/ASCRS Clinical Update Meeting. Kiawah, SC; June 2005.
• Payne JF, Squires CE, Escobar GP, Leonardi RA, Goshorn DK, Mingoia JT, Flack EC, Lindsey ML. Functional Alterations in Myocardial Fibroblasts from Ischemic Myocardium Post-Myocardial Infarction. Presented at the annual Horace G. Smithy Lecture Symposium. Charleston, SC; November 2003.

Publications

• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351: 2805-16.
• The VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with carly treatment of neovascular age-related macular degeneration with Pegaptanib Sodium: An Exploratory analysis. Retina 2005; 25: 815-27.
• Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
• Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2005; 113: 23-28.
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, for the ANCHOR Study Group. Ranibizumab versus Verteporfin for age-related macular degeneration. N Engl J Med 2006;355:1432-44.
• Diabetic Retinopathy Clinical Research Network. Comparison of the modified early treatment diabetic retinopathy study and mild macular laser grid photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125: 469-80.
• Diabetic Retinopathy Clinical Research Network. The risk of endophthalmitis following intravitreal injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 2007; 114: 454-6.
• Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007; 114: 525-36.
• Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology.2007 Oct;114(10):1860-7.
• Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina.2008 Jul-Aug;28(7):919-30.
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology.2008 Sep;115(9):1447-9.e1-10.
• Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology. 2008 Aug;115(8):1366-71, 1371.e1.
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008 Sep;115(9):1447-9, 1449.e1-10. Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK;
• Diabetic Retinopathy Clinical Research Network. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol.2008 May;145(5):894-901.
• SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. Am J Ophthalmol. 2009 Nov;148(5):725-732.e7. doi: 10.1016/j.ajo.2009.06.004. Epub 2009 Aug 11
• Browning DJ, Apte RS, Bressler SB, Chalam KV, Danis RP, Davis MD, Kollman C, Qin H, Sadda S, Scott IU; Diabetic Retinopathy Clinical Research Network. Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. Retina.2009 Mar;29(3):300-5.
• Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol.2009 Mar;127(3):245-51.
• The SCORE Study Research Group. A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch Ophthalmol, Sep 2009; 127: 1101 - 1114.
• The SCORE Study Research Group. A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion: The Standard Care vs corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. Arch Ophthalmol, Sep 2009; 127: 1115 - 1128.
• Diabetic Retinopathy Clinical Research Network. The course of response to focal/grid photocoagulation for diabetic macular edema. Retina.2009 Nov-Dec;29(10):1436-43
• Bhavsar AR, Googe JM Jr, Stockdale CR, Bressler NM, Brucker AJ, Elman MJ, Glassman AR; Diabetic Retinopathy Clinical Research Network. The Risk of Endophthalmitis Following Intravitreal Injection in the DRCR.net Laser-Ranibizumab-Triamcinolone Clinical Trials. Arch Ophthalmol. 2009 Dec;127(12):1581-3.
• Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol.2009 Mar;127(3):245-51.
• Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032. Epub 2010 Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris FL, Glassman AR, Ip MS, Miller KM, for the Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2010 May;117(5):946-953.
• Diabetic Retinopathy Clinical Research Network Writing Committee on behalf of the DRCR.net, Haller JA, Qin H, Apte RS, Beck RW, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010 Jun;117:1087-1093.e3
• Diabetic Retinopathy Clinical Research Network. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema. Retina. 2010 Oct;30(9):1488-95.
• Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 June;117(6):1064-1077.e35
• Friberg TR, Tolentino M for the LEVEL Study Group. Pegaptanib sodium as maintenanace therapy in neovascular age-related macular degeneration. Br J Ophthalmol 2010 94: 1611-1617.
• The CATT Research Group. Ranibizumab and bevacizuamb for neovascular age-related macular degeneration. N Engl J Med 2011;10.1056/NEJMe1103334 NEJM.org.
• The Diabetic Retinopathy Clinical Research Network. Expanded 2-year Follow-up of a Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology.2011 April; 118(4):609-14
• Diabetic Retinopathy Clinical Research Network. Randomized Trial Evaluating Short-Term Effects of Intravitreal Ranibizumab or Triamcinolone Acetonide on Macular Edema Following Focal/Grid Laser for Diabetic Macular Edema in Eyes Also Receiving Panretinal Photocoagulation. Retina.E-Print.
• Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS; Macugen 1013 Study Group. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.Ophthalmology. 2011 Jun;118(6):1107-18. doi: 10.1016/j.ophtha.2011.02.045. Epub 2011 May 6.PubMed [citation] PMID: 21529957
• Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; Diabetic Retinopathy Clinical Research Network. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus.Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6168-73. doi: 10.1167/iovs.11-7321.PubMed [citation] PMID: 21571677, PMCID: PMC3176025
• Schmitz-Valckenberg S, Alten F, Steinberg JS, Jaffe GJ, Fleckenstein M, Mukesh BN, Hohman TC, Holz FG; Geographic Atrophy Progression (GAP) Study Group.Reticular drusen associated with geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011 Aug 24;52(9):5009-15. doi: 10.1167/iovs.11-7235.PubMed [citation] PMID: 21498612
• Loftus JV, Sultan MB, Pleil AM; Macugen 1013 Study Group. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham. Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7498-505. doi: 10.1167/iovs.11-7613.PubMed [citation] PMID: 21896838
• Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J.Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20.PubMed [citation] PMID: 21764136
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.PubMed [citation] PMID: 22555112, PMCID: PMC3389193
• Mauschitz MM, Fonseca S, Chang P, Göbel AP, Fleckenstein M, Jaffe GJ, Holz FG, Schmitz-Valckenberg S; GAP Study Group. Topography of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012 Jul 26;53(8):4932-9.PubMed [citation] PMID: 22661483
• Grunwald JE, Daniel E, Ying GS, Pistilli M, Maguire MG, Alexander J, Whittock-Martin R, Parker CR, Sepielli K, Blodi BA, Martin DF for the CATT Research Group. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2012 Aug;119(8):1634-41.
• Chalam KV, Bressler SB, Edwards AR, Berger BB, Bressler NM, Glassman AR, Grover S, Gupta SK, Nielsen JS; Diabetic Retinopathy Clinical Research Network. Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8154-61. doi: 10.1167/iovs.12-10290.PubMed [citation] PMID: 23132803, PMCID: PMC3522439
• Chew EY, Clemons T, SanGiovanni JP, et al; AREDS2 Research Group. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology. 2012;119(11):2282-2289.
• DeCroos FC, Toth CA, Stinnett SS, Heydary CS, Burns R, Jaffe GJ, for the CATT Research Group. Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2012 Dec; 119(12):2549-57.
• Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF, for the Comparison of Age-related Macular Degeneration Treatments Trials Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2013 Mar;120(3):593-9.
• Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg and 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013 Mar;120(5):1046-56.
• Steinberg JS, Auge J, Jaffe GJ, Fleckenstein M, Holz FG, Schmitz-Valckenberg S;GAP Study Group. Longitudinal analysis of reticular drusen associated with geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013 Jun 10;54(6):4054-60. doi: 10.1167/iovs.12-11538.PubMed [citation] PMID: 23633663
• Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19): 2005-2015.
• Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J, for the Comparison of Age-related Macular Degeneration Treatments Trials Group. Macular morphology and visual acuity in the Comparison of Age-related Macular Degenration Treatments Trials. Opthalmology. 2013 Sep;120(9):1860-70.
• Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Juang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF for the Comparison of Age-related Macular Degeneration Treatments Trials Group. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology. 2013 Oct;120 (10):2035-41.
• Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Juang J, Ying GS, Hagstrom SA, Winter K, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 2013 Dec 3 Epub ahead of print.
• Chew EY, Clemons TE, SanGiovanni JP, et al; Age-Related Eye Disease Study 2 (AREDS2) Research Group. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132(2):142-149.
• Bonds DE, Harrington M,Worrall BB, et al; Writing Group for the AREDS2 Research Group. Effect of long-chain #-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Intern Med. 2014;174(5):763-771.
• Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF, for the Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 2014;121:150-161.
• Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying G, Hagstrom SA, Winter K, Maguire MG for the Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 2014;121:656-666.
• Chew EY, Clemons TE, Agron E, Launer LJ, Grodstein F, Bernstein PS, for the Age-Related Eye Disease Study 2 (AREDS2) Research Group. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function The AREDS2 Randomized Clinical Trial. JAMA. 2015;314(8):791-801. doi:10.1001/jama.2015.9677
• Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX-DME Study Group. Am J Ophthalmol. 2019 Jun;202:91-99. doi: 10.1016/j.ajo.2019.02.005. Epub 2019 Feb 14.
• Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. Abdelfattah NS, Hariri AH, Al-Sheikh M, Pitetta S, Ebraheem A, Wykoff CC, Sadda SR; TREX-AMD Study Group. Am J Ophthalmol. 2018 Aug;192:84-90. doi: 10.1016/j.ajo.2018.05.008. Epub 2018 May 12.
• Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.Payne JF, Clark WL, Bruce BB, Wykoff CC, Brown DM, Menke BM, Iverson SM, Allen KF, Boyer DS; Treat & Extend Protocol in Patients with Diabetic Macular Edema Study Group. Ophthalmology. 2018 Aug;125(8):1304-1306. doi: 10.1016/j.ophtha.2018.03.046. Epub 2018 May 3. No abstract available.
• Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Abdelfattah NS, Al-Sheikh M, Pitetta S, Mousa A, Sadda SR, Wykoff CC; Treat-and-Extend Age-Related Macular Degeneration Study Group. Ophthalmology. 2017 Feb;124(2):215-223. doi: 10.1016/j.ophtha.2016.10.002. Epub 2016 Nov 15. PMID: 27863845
• Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR; TREX-AMD Study Group. Ophthalmology. 2015 Dec;122(12):2514-22. doi:10.1016/j.ophtha.2015.08.009. Epub 2015 Sep 29.
• Sun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP. One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study. Ophthalmol Retina. 2019 Dec;3(12):1107-1109.
• Glassman AR, Wells JA 3rd, Josic K, Maguire MG, Antoszyk AN, Baker C, Beaulieu WT, Elman MJ, Jampol LM, Sun JK. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020 Sep;127(9):1201-1210.
• Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, Salehi-Had H, Wells JA 3rd, Maguire MG, Stockdale CR, Martin DF, Sun JK; DRCR Retina Network. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2020 Dec 15;324(23):2383-2395.
• Khanani AM, Patel SS, Gonzalez VH, Moon SJ, Jaffe GJ, Wells JA, Kozma P, Dugel PU, Maturi RK. Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema. Ophthalmol Sci. 2021 Jul 14;1(3):100040.
• Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. PMID: 35085503.
• Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. PMID: 38158159.